Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPC-61815 tolerability in CHF patients unable to take oral intake
NCT03962101Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Jun 2019
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in heart failure (HF), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Percentage of Subjects With Treatment-Emergent Adverse Events and Serious TEAEs at 15 days. Started Jun 2019; status: completed.
02
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03962101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03962101.